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Abstract
Background One in three patients with Crohn’s disease
will develop a perianal fistulae, and one third of these will
achieve long-term healing or closure. A barrier to con-
ducting well-designed clinical trials for these patients is a
lack of understanding of prognostic factors. This system-
atic review sets out to identify factors associated with
prognosis of perianal Crohn’s fistulae.
Methods This review was registered on the PROSPERO
database (CRD42016050316) and conducted in line with
PRISMA guidelines along a predefined protocol. English-
language studies assessing baseline factors related to out-
comes of fistulae treatment in adult patients were included.
Searches were performed on MEDLINE and Embase
databases. Screening of abstracts and full texts for eligi-
bility was performed prior to extraction of data into pre-
designed forms. Bias was assessed using the QUIPS tool.
Results Searches identified 997 papers. Following removal
of duplicates and secondary searches, 923 were screened
for inclusion. Forty-seven papers were reviewed at full-text
level and 13, 2 of which were randomised trials, were
included in the final qualitative review. Two studies
reported distribution of Crohn’s disease as a prognostic
factor for healing. Two studies found that CARD15
mutations decreased response of fistulae to antibiotics.
Complexity of fistulae anatomy was implicated in prog-
nosis by 4 studies.
Conclusions This systematic review has identified potential
prognostic markers, including genetic factors and disease
behaviour. We cannot, however, draw robust conclusions
from this heterogeneous group of studies; therefore, we
recommend that a prospective cohort study of well-charac-
terised patients with Crohn’s perianal fistulae is undertaken.
Keywords Crohn’s disease  Perianal fistulae  Prognosis 
Systematic review
Introduction
Crohn’s disease (CD) is an inflammatory condition which
can affect any part of the gastrointestinal tract. It is char-
acterised by chronic inflammation all the way through the
intestinal wall. Crohn’s disease typically follows one of
three behaviour patterns: inflammation only, stricturing,
and penetrating [1]. Penetrating disease is typically char-
acterised by formation of a fistulae (an abnormal connec-
tion between two epithelial surfaces). This can happen
between intestinal loops (enteroenteric), intestine, and skin
(enterocutaneous), or the anorectum and buttock skin (pe-
rianal). The incidence of perianal fistulas in CD is around
30% [2].
A fistulae is typically managed with sepsis control,
through incision and drainage of any abscess, placement of
a seton, and immune modulation by drugs such as aza-
thioprine or infliximab (anti-TNF-a therapy) [3, 4]. A
number of alternative surgical procedures might also be
considered [3]. In serious cases, a stoma might be offered,
often as a prelude to proctectomy [4]. This condition can
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have a significant impact on patients’ quality of life [5–7].
As few as one in three patients will achieve long-term
healing of their fistulae [8]. Consequently, health care costs
of anal fistulae in CD are high due to drug therapies [9, 10].
It is not surprising that this condition has been identified as
a research priority in two recent research priority setting
exercises [11, 12].
The aetiology of CD is complex and multifactorial.
Recent genomic studies have identified several loci of
susceptibility [13–15]. Several of these genes are impli-
cated in aberrant immune responses. Environmental factors
such as smoking are thought to play a key part in disease
behaviour [16], as in altered intestinal microbiome [17]
[18]. These are baseline disease or demographic factors
that might be implicated in disease behaviour and prog-
nosis. On top of these systemic mechanisms, localised
mucosal damage and aberrant or failed repair mechanisms
likely contribute to persistence of fistulae [2, 19].
Randomised controlled trials (RCTs) are the gold stan-
dard in clinical research, and these are sorely needed to
guide treatment of fistulating perianal CD. To design trials,
we need to balance prognostic factors across study arms to
limit confounding and produce reliable results [20].
The aim of the present study was to systematically
review the literature and identify baseline prognostic fac-
tors relevant to the treatment of fistulating perianal CD.
Materials and methods
This review was registered on the PROSPERO database
(CRD42016050316) and conducted in line with Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) guidelines using a predefined protocol.
The inclusion criteria were: publication during or after
1980; study size C50 patients with rectovaginal or perianal
fistulas; fistulae cause by CD; patients aged 16 years or
over; fistulae is baseline health state (startpoint [20]) of the
study. Exclusion criteria were: CD without fistulae; paper
only reports intervention as opposed to demographic or
disease status; covariates; paper only includes treatment
outcomes as opposed to analysing by demographic or
disease status factors. Publications not in English were also
excluded due to resource constraints.
Information sources were MEDLINE (1946 to October
26, 2016) and Embase (1974 to October 26, 2016) via
Ovid. Searches, which used no limits, combined thesaurus
and free-text terms (see Fig. 1).
Results from bibliographic databases were combined
with papers through secondary searches of bibliographies
and papers of known relevance identified by clinical topic
experts, and duplicates removed. Titles and abstracts of
citations were screened against the eligibility criteria (by
GB), with secondary review and resolution of queries (by
ML and DH). Potentially eligible full texts were retrieved
and the process repeated, with reasons for rejection
recorded.
Data were extracted into predesigned tables (by GB) and
findings confirmed (by ML). We extracted data on demo-
graphics of the patients and specific details about their
condition, including: age; gender; smoking status; duration
of disease; location of disease; number of fistulas; treat-
ments; and outcome data on ‘response’ or ‘healing’, that is
:fistulae closure, no further discharge from fistulae, or no
fistulae recurrence, however defined. Risk of bias (RoB) in
individual studies was assessed by two reviewers (GB and
ML) using the Quality In Prognosis Studies tool (QUIPS)
tool [21]. This tool assesses 6 domains: study participation,
study attrition, prognostic factor measurement, outcome
measurement, study confounding, and statistical analysis
and reporting. We recorded statistical methods used and
summary measures, however presented, including odds
ratios, relative risks, hazard ratios with confidence inter-
vals, tests of significance (p values). We conducted a nar-
rative (descriptive) synthesis with results structured by type
of prognostic factor.
Results
The PRISMA study selection flow chart is shown in Fig. 2.
Study comparisons
Searches identified 997 papers. Following removal of
duplicates and secondary searches, 923 were screened for
inclusion. Forty-seven papers were reviewed at full-text
level. Thirty-four papers were rejected at this stage for the
following reasons: no prognostic factors reported (n = 11),
\50 patients with fistulas caused by CD (n = 9), CD
without fistulas (n = 4), fistulae was an endpoint (n = 3),
development of fistulae was a factor in natural history of
Crohn’s disease (n = 2), paper was a narrative review
(n = 3), or paper was a systematic review (n = 2). This
left 13 papers for qualitative review.
Fig. 1 Search terms used in paper selection
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Study demography and design
Of the 13 studies identified, 2 were published between
1995 and the end of 1999 [22, 23], 7 between 2000 and the
end of 2009 [24–30], and 4 between 2010 and 2014
[31–34]. Studies and characteristics are summarised in
Table 1.
All studies took place in the USA (n = 3) [23, 27, 30])
or Europe (Germany (n = 3) [22, 25, 28], France (n = 2)
[32, 34], the UK (n = 1) [24], the Netherlands (n = 1)
[31], Austria (n = 1) [29], Spain (n = 1) [26], and Portu-
gal (n = 1) [33]). The institutional setting was a teaching
hospital in all cases.
Ten of the studies were prospective: either observational
(n = 8) [22, 25, 26, 28–30, 33, 34] or RCTs (n = 2)
[23, 31]. The remaining 3 studies were retrospective
[24, 27, 35]. The follow-up period for studies ranged from
7 weeks to 27.3 years.
Different statistical methods were used to evaluate
results. The techniques used were Fisher’s exact test
(n = 9) [23–25, 27–31, 33], Chi-square test (n = 7)
[23, 25–27, 30, 31, 33], mean with standard deviation
(n = 5) [26, 29, 31, 33, 34], Mann–Whitney U test (n = 4)
[24, 28, 31], Kaplan–Meier method (n = 4)
[22, 25, 32, 34], log-rank test (n = 4) [22, 25, 32, 34], Cox
proportional hazards regression model (n = 3) [22, 32, 34],
95% confidence Intervals (n = 2) [26, 33], odds ratios
(n = 2) [23, 33], Wilcoxon rank tests (n = 2) [22, 28],
median with interquartile range (n = 2) [31, 32], log-
likelihood ratio (n = 1) [26], Kruskal–Wallis test (n = 1)
[25], Kolmogorov–Smirnov test (n = 1) [33], and Hardy–
Weinberg test (n = 1) [33]. Statistical methods and
potentially confounding variables recorded are shown in
Table 2.
Outcomes
Identified prognostic factors were related to various out-
come measures defined differently in the 13 papers.
Common outcome terms were healing, response, complete
response, partial response, and recurrence. A summary of
various definitions and common ‘headings’ used is pre-
sented in Table 3.
Bias
Risk of bias findings are presented in Table 3. Overall risk
of bias in the studies was judged to be low for 7
[26, 28, 29, 31–34, 36] and moderate for 6 studies
[23–25, 30, 37] [24]. Study attrition was typically low. The
domains most commonly at high risk of bias were study
confounding (n = 5) [22, 24, 25, 28, 30] and statistical
analysis and reporting (n = 6) [26, 30–33, 37]. This bias
assessment is shown in Table 4.
Prognostic factors
Prognostic factors were divided into those associated with
patient characteristics, disease characteristics, and envi-
ronmental characteristics. These are summarised in
Table 5.
Patient characteristics
Two papers found that patient sex was significant. A RCT
of infliximab versus placebo (n = 94) found that males
were significant more likely than females to reach the
primary endpoint (p\ 0.001) versus (p = 0.28) [23].
Another paper (n = 81) found that time for closure of
fistulae was significantly shorter for men than women, at
11.7 months versus 21.0 months (p = 0.03) [HR 0.59,
(95% CI 0.36–0.96)] [34]. Three papers found sex had no
significant association with outcome. One trial (n = 70)
found sex was not significant to the ‘response’ of patients
(p = 0.74) [31] and another (n = 108) found no difference
between the sexes (p[ 0.05) [26]. A retrospective study
(n = 156) found that sex was not a significant prognostic
factor. (p = 0.12) [HR 1.46, (95% CI 0.89–2.35)] [32]
Only 1 trial (n = 108) assessed age as a prospective
factor and did not find it to be significant (p[ 0.05) [26].
Race was evaluated in 1 study (n = 70) as ‘Caucasian
versus other’ and was found not to be a significant pre-
dictor of healing (p = 0.39) [31].
Studies did not clearly report baseline/historic use of
medications; this was reported as previous or current use of
immunosuppression and therefore not included in this
study.
Fig. 2 PRISMA flow diagram
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Genetics
Two papers evaluated the clinical response of NOD2/
CARD15 variant carriers versus wild-type patients to
antibiotic therapy. One study (n = 54) found that that
complete fistulae response was more likely with wild-type
(33 vs. 0%, p = 0.02) [28]. The other (n = 203) found that
those without the mutation were more likely to show
Table 3 Common outcome groups and definitions used
Common outcome measure Definition given in paper
‘Healed’/‘healing’/‘complication
healed’ (n = 4)
No discharge on history or examination, with healing of the external opening [24]
Complete closure of fistulae without sign of activity or pain for at least a month [37]
Complete healing or successful dilation of anal stenosis, after surgical intervention [30]
Non-defined [27]
Response (n = 3) C50% reduction in fistulas [31]
Maintained fistulae healing; PDAI 2.8 ± 2.4 [29]
Absence of fistulae drainage, even after compression for at least 4 weeks [33]
Complete response (n = 4) The complete cessation of drainage from all fistulas despite gentle finger compression [26]
Absence of any draining fistulas [23]
Absence of any drainage fistulas despite gentle finger compression [28]
PDAI 0.8 ± 1.0 fistulae closure or absence of any draining fistulas despite gentle finger compression [29]
Partial response (n = 2) At least 50% reduction from baseline in the number of fistulas or drainage for at least 4 consecutive weeks
after the discontinuation of drug infusions [26]
Reduction of 50% or more from baseline in the number of draining fistulas [28]
Recurrence (n = 4) Presence of fistulae openings among patient who experienced fistulae closure [32]
Reopening of a former track or presence of new fistulae after primary response [34]
Reappearance of active perianal fistulas or associated abscesses after prior inactivation or healing [37]
Recurrence of the same or different complication after a period of complete healing [30]
PDAI perianal disease activity index
Table 4 Risk of bias using QUIPS tool
Overall risk
of bias
1. Study
participation
2. Study
attrition
3. Prognostic factor
measurement
4. Outcome
measurement
5. Study
confounding
6. Statistical analysis
and reporting
Bell [24] Moderate L L L M H M
Dewint [31] Low L L M L M H
Loffler [25] Moderate M L M M H M
Luna-Chadid
[26]
Low L L H L L H
Present [23] Moderate M M L L M M
Gaertner
[39]
Moderate L L H H M M
Angelberger
[61]
Low L L M L H M
Bougen [32] Low L L L M L H
Dejaco [29] Low L M M L L M
Freire [33] Low L L L M L H
Haennig [34] Low M M L L L M
Makowiec
[37]
Moderate L M M L H H
Michelassi
[30]
Moderate M L M L H H
L low risk of bias, M moderate risk of bias, H high risk of bias
QUIPS Quality in Prognostic Studies
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Table 5 Studies and prognostic factors assessed
Paper Clinical endpoints Significant prognostic factors Insignificant prognostic factors
Bell [24] ‘Healed’—no discharge on history or
examination, with healing of the
external opening
Rectal Crohn’s made proctectomy more
likely than those with no rectal
involvement (p =\0.001)
Complex did not take significantly
longer to heal than simple (p = 0.69)
‘Persistent fistulae’—not defined Complex perianal took an average of 6
procedures over 2 or more years
The presence of a rectovaginal fistulae
was not predictive of the need for a
proctectomy (p = 0.25)
‘Maintenance with a seton’—not defined This is significantly more procedures
than simple (3 treatments, p = 0.002)
No association between presence of
rectal CD and rectovaginal fistulae
(p = 0.085)
‘Sepsis’—if an abscess formed at the
fistulae site
This is significantly more than
rectovaginal (3 treatments, p = 0.01)
‘None healed’ ‘death’ This is significantly more procedures
than abdominal wall (2 treatments,
p = 0.0005)
This is significantly more time than
internal fistulae (1 treatment, p = 0.002)
Complex fistulae took on average
42.8 months to heal
Rectovaginal fistulae took significantly
shorter time to heal (median of
26 months) than perianal fistulae
(p = 0.05)
Abdominal wall fistulae took
significantly shorter time to heal
(median of 6.3 months) than perianal
fistulae (p = 0.0001)
Enteroenteric took significantly shorter
time to heal (median of 9.4 months)
than perianal fistulae (p = 0.03)
Dewint [31] ‘Response’ – None Sex (p = 0.74)
C50% reduction in no. of fistulae Race, Caucasian versus other (p = 0.39)
‘Remission’ – Seton (p = 0.90)
100% closure of draining fistulae Stoma (p = 0.30)
Smoker (p = 0.64)
Previous treatment with infliximab
(p = 0.63)
Loffler [25] ‘Long-term success’—whether or not
patients have fistulae persistence or
recurrence over 60 months
98% of patients with anorectal or
rectovaginal disease also had a
manifestation in colon/rectum. This
was significantly higher than in patients
without anorectal or rectovaginal
fistulae (p\ 0.001)
Complex fistulae in comparison with
simple fistulas, there was a strong trend
to a difference in outcome of 5 years
(p = 0.2113)
Luna-Chadid
[26]
‘Complete response’—the complete
cessation of drainage from all fistulas
despite gentle finger compression
None Age
‘Partial response’—at least 50%
reduction from baseline in the number
of fistulas or drainage for at least 4
consecutive weeks after the
discontinuation of drug infusions
Sex
‘Response for rectovaginal fistulae’—
closure documented by physical
examination
Smokers
Duration of fistulising disease
(no p value given, just says the p value is
not significant)
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Table 5 continued
Paper Clinical endpoints Significant prognostic factors Insignificant prognostic factors
Present [23] ‘Complete response’—absence of any
draining fistulae
Males (p\ 0.001)are more likely than
females (p = 0.28) to reach primary
endpoint when in infliximab group as
compared to placebo group
None
A fistulae was considered to be closed
when it no longer drained despite
gentle finger compression
Gaertner
[27]
‘Healing’—not defined None There were no significant associations
found between fistulae healing and the
duration of CD, initial site of CD,
previous fistulae disease, and cigarette
smoking
Angelberger
[59]
‘Complete response’ -absence of any
draining fistulae despite gentle finger
compression
Complete fistulae response was
significantly higher in patients with
NOD2/CARD15 wild type
Median HBD-2 gene copy number was
not significantly different between the
responders and non-responders
(p = 0.92)
‘Partial response’—reduction of 50% or
more from baseline in the number of
draining fistulae
(p = 0.02) Duration of perianal fistulating disease
(p = 0.844)
Smoking (p = 0.239)
Association between complete response
and median number of draining fistulae
(p = 0.18)
Rate of patients with more than one
draining fistulae (p = 0.32)
Bougen [32] (1) Fistulae closure = absence of any
draining by fistulae openings at one
visit
Significant predictors of perianal fistulae
closure: prior abdominal surgery
Sex (p = 0.12) HR 1.46 (95%
0.89–2.35)
(2) Recurrence of PCD = presence of
fistulae openings among patient who
experienced fistulae closure
(p = 0.0097) HR 0.43 (95% CI 0.21–0.8)
(3) Recurrence of abscess after IFX
initiation
(4) Sustained fistulae closure for patients
without any recurrence
Dejaco [29] ‘Response’—maintained fistulae healing,
PDAI 2.8 ± 2.4
The duration of fistulising disease was a
significant prognostic factor (p = 0.04)
Smoking (p = 0.3)
‘Complete Response’—PDAI 0.8 ± 1.0,
fistulae closure or absence of any
draining fistulae\despite gentle finger
compression
‘No response’ –
PDAI 7.4 ± 3.1
Freire [33] ‘Response’—absence of fistulae
drainage, even after compression for at
least 4 weeks
Clinical response of perianal fistulae to
antibiotics was significantly higher in
patients without the CARD15 mutation
(p = 0.041)
None
OR 8.16 (95% CI 0.97–68.74)
Haennig [34] ‘Clinical response’—complete closure of
the fistulae track with no further
discharge from the opening(s) on the
gentle application of pressure
The time for closure of fistulae was
significantly shorter for men than
women (p = 0.03) HR 0.59 (95% CI
0.36–0.96)
Recurrence after initial fistulae closure—
tobacco (p = 0.41)
‘Primary response’—closure had been
sustained for at least 4 months
11.7 versus 21.0 months Ileocolonic location of CD (p = 0.10)
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Table 5 continued
Paper Clinical endpoints Significant prognostic factors Insignificant prognostic factors
‘Recurrence’—reopening of a former
track or presence of new fistulae after
primary response
The time for closure was significantly
shorted for simple fistulae compared to
complex fistulae (p\ 0.001) HR 0.31
(0.16–0.62)
Rectovaginal fistulae (p = 0.24)
2 versus 15.3 months
Rectovaginal fistulae took a significantly
longer time to close than perianal
(p = 0.02) HR 0.44 (0.22–0.91)
12 versus 30.6 months
Makowiec
[37]
‘Inactivation of perianal fistulas and
abscesses’—cessation of purulent
discharge from fistulae and
disappearance of perianal pain
Ischiorectal and transsphincteric fistulae
recurred more frequently than low
fistulas (p = 0.007)
None
‘Healing’—complete closure of fistulae
without sign of activity or pain for at
least a month
Low fistulas had a better prognosis
(higher healing rate) than
transsphincteric
‘Reopening of fistulae’—reappearance of
perianal fistulas after prior healing
or ischiorectal fistulas
‘Symptomatic recurrence’—
reappearance of active perianal fistulae
or associated abscesses after prior
inactivation or healing
(p = 0.015)
The presence of rectal disease indicated
that a patient was significantly more
likely to have recurrence (p = 0.041)
Fistulae healed better in patients without
than in those with rectal disease
(p = 0.017)
If presence of stoma are more likely to
heal (p = 0.005)
Michelassi
[30]
‘Persistence’—persistence of a
complication after surgical intervention
A patient is significantly less likely to
heal from a perianal complication when
there is rectal involvement (p\ 0.05)
None
‘Development’—development of a
complication different from the
original one as a consequence of
surgical intervention
49.1 versus 19.3%
‘Recurrence’—recurrence of the same or
different complication after a period of
complete healing
A patient is significantly more likely to
heal when they have a single
complication compared to having
multiple complications (p\ 0.05)
‘Complication healed’—complete
healing or successful dilation of anal
stenosis, after surgical intervention
48.6 versus 28.2%
‘Sepsis controlled’—anorectal sepsis
controlled as consequence of surgery
Patients with rectal involvement had a
significantly higher chance of
proctectomy (p\ 0.0001)
77.6 versus 13.6%
Patients with multiple complications had
significantly higher chance of
proctectomy (p\ 0.05)
23 versus 10%
CD Crohn’s disease, PDA perianal disease activity index, PCD perianal Crohn’s disease
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clinical improvement when treated with antibiotics (7.7 vs.
40.5%, p = 0.041) [33]. Both of these studies relied on
fistulae drainage and had small numbers in the variant
carrier group; therefore, caution should be exercised in
interpreting these results.
Disease duration and location
A prospective observational study (n = 52) found the
duration of fistulating disease was a significant prognostic
factor, although strength and direction of association was
not clearly reported (p = 0.04) [29]. Two prospective
studies found the duration of perianal fistulating disease
was not significant—again measures used to assess this
were not clear [26, 28]. A retrospective study (n = 226)
found no significant associations between fistulae healing
and the duration of CD [27].
Two papers reported patients with ileal CD only (in
association with perianal disease) were significantly more
likely to have better outcomes than those with other disease
distributions. One RCT (n = 94) noted complete fistulae
response was more likely in those with ileal and colonic
disease (OR 5.1, p = 0.01) than those with isolated colonic
disease (OR 2.3 p = 0.35) [23]. A retrospective study
(n = 156) found patients with ileocolonic disease were
more likely to achieve fistulae closure [HR 1.59
(1.08–2.34) p = 0.017] compared to those with colonic
disease [HR 0.86 (0.58–1.27) p = 0.54] on univariate
analysis [32]. On multivariate analysis, ileocolonic beha-
viour was positively associated with fistulae healing [HR
1.88 (1.08–3.32) p = 0.025]. This finding was not upheld
by 1 prospective study (n = 81), and 1 retrospective study
(n = 226) which found no association between fistulae
healing and the initial site of CD [27, 34]. Three
prospective studies found rectal involvement in CD was a
predictor of poor fistulae healing [24, 25, 30].
Fistulae anatomy
Three papers identified complexity of fistulae anatomy as a
prognostic factor. Prospective studies found that compared
to simple fistulae, complex fistulae required more treat-
ments (n = 86) (p = 0.02) [36] and took longer to heal
(15.3 vs. 2 months) (n = 81) (p\ 0.001) [HR 0.31 (95%
CI 0.16–0.62)] [34]. A retrospective study (n = 156)
demonstrated that simple fistulae was associated with fis-
tulae closure [HR 2.53 (95% CI 1.43–4.45) (p = 0.006)]
[32] Another study (n = 147) found a trend towards worse
outcomes at 5 years for complex versus simple fistulae
(p = 0.2113) [25].
One study (n = 224) found that a patient with multiple
fistulae was less likely to achieve healing than a patient
with a single fistulae [48.6 vs. 28.2% (p\ 0.05)] [30]. This
was not consistent across all studies [24, 25].
Presence of a rectovaginal fistulae was not thought to be
a prognostic factor for overall perianal fistulae healing
(n = 81) [27].
Environmental characteristics
Six studies evaluated smoking, and none of these found it
to be a significant prognostic factor [26–29, 31, 34]. This is
summarised in Table 6.
Discussion
To our knowledge, this is the first systematic review to
assess prognostic factors in fistulating perianal CD. It has
identified candidate prognostic factors including NOD2/
CARD15, duration of fistulating disease, distribution of
CD, and fistulae anatomy. These require further robust
assessment before they can be used to inform research or
clinical practice. The challenges to prognostic research in
this field are many, including lack of standardised outcome
measures and timing of outcome measurement.
The NOD2 and CARD15 variant genes had a significant
association with fistulae response to antibiotics in 2 studies
[28, 33]. Prior work has found associations between disease
severity and expression of the various alleles, particularly
with aggressive luminal disease requiring early and repe-
ated surgery [38–40]. This suggests that these are plausible
factors related to the prognosis of fistulating perianal CD,
although there is insufficient evidence presented at this
point to understand strength of association, or modulating
factors.
Table 6 Studies assessing
smoking as a prognostic factor
in outcome of perianal Crohn’s
fistulae
Study Total patients (n) Smokers (n) p value Prospective/retrospective
Dewint [31] 70 22 0.64 Prospective
Luna-Chadid [26] 108 54 [0.05 Prospective
Angelberger [28] 54 29 0.239 Prospective
Dejaco [29] 52 32 0.3 Prospective
Haennig [34] 81 23 0.41 Prospective
Gaertner [27] 226 32 [0.05 Retrospective
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Duration of fistulating disease was significant in 1 study
(with unclear direction), but not in 2 others. Long-standing
fistulae have been shown to undergo epithelialisation and
behave in a similar fashion to skin, and this may reduce the
ability to heal [41–43]. If track epithelialisation is the
underlying mechanism, then it may be reasonable to con-
sider fistulae duration as a prognostic factor (or a proxy of a
prognostic factor).
Disease distribution is possibly a prognostic factor, with
ileal disease associated with a better prognosis and colonic
or rectal disease associated with a worse prognosis.
Guidelines advocate early assessment for proctitis in
Crohn’s fistulae, as this impacts clinical strategy and out-
come [4, 44, 45]. Proctitis has been associated with higher
rates of proctectomy in previous studies, suggesting that
this factor has a role in predicting outcomes in these
patients [46].
The behaviour of the fistulating process is most likely a
factor in healing, both in terms of complexity and number.
Those with complex anatomy (multiple branching tracks
crossing large proportions of the anal sphincter) are at risk
of recurrent sepsis [47]. Unfortunately, terminology used to
define ‘complex’ and ‘simple’ is not standard across the
literature. Complexity of fistulae anatomy is more than
location and number of branches. Magnetic resonance
imaging offers the ability to assess volume and length of
fistulae tracks [48]. It is plausible that a longer or large-
volume fistulae track could take longer to heal than a short-
or low-volume track. This is potentially an important
prognostic marker and therefore would merit further
assessment.
Patient demographics including sex may not have a role
to play; the majority of studies reviewed found no rela-
tionship between sex and outcome, and those that did
identify statistical differences obtained conflicting results.
This may reflect sampling issues.
None of the studies reviewed found that smoking was a
significant prognostic factor in fistulae outcomes. Smoking
has been shown to be associated with poor disease control,
and smoking cessation is widely advised in CD [49–51].
Given this, it is interesting that it is not a significant factor
here. This could be for a number of reasons: bias of design
of studies through definition of smoking (patient reported
vs. carbon monoxide testing), or size or sampling of
patients; that there is no mechanistic role for smoking in
the formation of perianal fistulae; or that disease is already
‘bad’ and smoking has no additive effect.
The number of prognostic factors identified was limited
by the number of studies reporting baseline factors with
appropriate analysis. Even if cohorts had been well
described, it would not have been possible to perform a
meta-analysis in this setting as there was little consistency
across study endpoints. There were 5 major groups of
outcome (healed, response, complete response, partial
response, recurrence), with an average of 4 definitions for
each outcome. Definition of recurrence was fairly consis-
tent across studies. The definition of healed included an
asymptomatic fistulae, a non-draining fistulae on com-
pression, and a change in the perianal disease activity index
(PDAI). These are relatively subjective measures; even the
PDAI has subjective elements [52], at a single time point. It
is clear that there are issues to be addressed before further
studies are undertaken to investigate this further.
There are limitations to consider in this review. Initial
screening by a single reviewer to select studies and extract
data increased the possibility that relevant reports were
discarded [53, 54]. Despite this, we had multiple checks in
place to support the single reviewer process, including
screening of discarded abstracts for key papers by a second
reviewer. This, coupled with support from clinical topic
experts and a robust bibliography search, meant that we
were confident that we had identified the majority of papers
reporting prognostic factors.
This study used a broad search strategy to identify as
many candidate papers as possible and used a tool appro-
priate for the assessment of prognostic factors (QUIPS).
The validity of the findings is supported by the prognostic
role of some reported factors in other aspects of inflam-
matory bowel disease. There are diminishing marginal
returns from the use of databases additional to MEDLINE
and Embase, with some such as CINAHL rarely retrieving
unique references for many topic areas [55, 56]. For this
reason, we believe our search strategy is associated with a
low risk of bias.
It is important that any future prognostic study captures
the above factors and uses a standardised well-defined
outcome measure. A well-conducted cohort study will
allow all the above factors to be properly assessed using
appropriate multivariate statistical models [57, 58]. Given
the prevalence and incidence of perianal CD, it might be
possible to use the resulting data to inform novel study
designs. Clear understanding of confounding factors might
allow for trials within cohorts, Bayesian modelling or
interrupted time series as alternatives to classical trial
designs.
Conclusions
This systematic review has identified potential prognostic
markers for outcomes in fistulating perianal CD, including
genetic factors and disease behaviour. We cannot, how-
ever, draw robust conclusions from this heterogeneous
group of studies. We recommend that future studies include
well-characterised cohorts and use a consistent endpoint
for reporting.
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